



**FemmePharma**

GLOBAL HEALTHCARE, INC.

**FOR IMMEDIATE RELEASE**

**CONTACT: Alison Dickman**

**[alison@comsolutionsgroup.com](mailto:alison@comsolutionsgroup.com)**

**(215) 884-6499**

## **Novel Investigational Drug May Help 26 Million American Women Suffering From Breast Pain**

### ***Clinical Trial for Fibrocystic Breast Disease Being Conducted Nationwide***

**WAYNE, PA – June 27, 2007**—A clinical trial for a much needed treatment option for pain associated with fibrocystic breast disease is in progress nationwide. The severely debilitating symptoms such as breast pain, affect about 26 million women in the United States alone but it is often left untreated leaving women feeling hopeless.

As many as 50 percent of American women talk to their physicians about breast pain including swelling, tenderness and lumps that increase prior and during menstruation and may continue for several days. The pain is not only physical. Psychological stress is often associated with undergoing mammograms, ultrasound scans and breast biopsies, techniques frequently utilized by physicians to rule out other diseases of the breast.

“Breast pain associated with fibrocystic breast disease can be physically impairing, leaving women unable to cope with basic daily functions, yet 85 percent of women don’t receive treatment,” said Gerianne Tringali DiPiano, President and CEO of FemmePharma Global Healthcare, the company sponsoring the study. “We hope news of this trial will compel women with breast pain associated with fibrocystic breast disease who have been previously diagnosed to seek a study center in their area.”

Physicians at centers nationwide will enroll women who have breast pain associated with fibrocystic breast disease.

“The trial allows us to assess a new dosage form of an active pharmaceutical ingredient with a demonstrated safety and efficacy profile. We expect that the new dosage forms will provide a new treatment option for this very important disease state,” added Bruce J. Levine MD, FACOG, and investigator of the trial.

For more information about the clinical trial and enrollment please visit the Clinical Trial section of FemmePharma Global Healthcare’s website at [www.femmepharma.com](http://www.femmepharma.com).

### **About Breast Pain Associated with Fibrocystic Breast Disease**

■ 37 West Avenue • Second Floor  
■ Wayne, Pennsylvania 19087  
■ Tel: 610.995.0801  
■ Fax: 610.995.0825

Breast pain can impair a woman's ability to work, participate in her daily activities, embrace a child or have an intimate relationship with her partner. In addition, breast pain frequently causes increased anxiety and stress in a woman's life as a result of dealing with pain each month.

Approximately 15 percent of women who experience breast pain require prescription medication. Currently there is only one FDA approved prescription medication for pain associated with fibrocystic breast disease. However, this medication typically produces unwanted systemic side effects, which often causes women to stop their necessary treatment. In many cases, women are sent home and told to ice their breasts or purchase a tighter fitting brassiere leaving them feeling hopeless.

**About FemmePharma Global Healthcare, Inc.**

FemmePharma Global Healthcare, Inc. is committed to improving the health of women and is exploring an innovative, investigational drug that provides adequate relief with minimal unwanted side effects for women suffering from pain associated with fibrocystic breast disease.

Founded in 1996, FemmePharma Global Healthcare is focused on developing safe and effective drugs minimizing or eliminating the side effects associated with many drug therapies by designing treatments in a way that suits the female anatomy and physiology. The company has already scored great success in the development of a treatment for endometriosis through Phase 2. As a result, KV Pharmaceuticals bought the global rights and continues its development of the product.

Other current endeavors include a product to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.

**For more information or to schedule interviews, call Alison Dickman at 215-884-6499.**